Source comparison
Comparison Table: Kisspeptin vs Conventional Ovulation Induction
Before selecting an ovulation induction approach, understanding the mechanistic and practical differences matters. The following table compares kisspeptin-based protocols to standard first-line and second-line treatments for anovulatory PCOS. Clomiphene Citrat
This comparison does not assign a generated winner or score.
- Before selecting an ovulation induction approach, understanding the mechanistic and practical differences matters. The following table compares kisspeptin-based protocols to standard first-line and second-line treatments for anovulatory PCOS.
- Clomiphene Citrate
- Estrogen receptor antagonist. Blocks negative feedback at hypothalamus and pituitary, increasing endogenous FSH
- 60–75% in clomiphene-sensitive PCOS
- Moderate (10–15% develop ≥3 mature follicles)
- Oral tablet, 5 days per cycle
- First-line standard. Effective but blind to central pulse defect; 25% clomiphene-resistant
- Letrozole
- Aromatase inhibitor. Reduces estrogen synthesis, releasing FSH from negative feedback suppression
- 70–80% in first-line use
- Low-moderate (5–10% multiple follicles)
- Current preferred first-line per ASRM. Lower multiple pregnancy rate than clomiphene
- Exogenous Gonadotropins (FSH)
- Direct ovarian stimulation with recombinant FSH. Bypasses hypothalamus entirely
- 85–95% with dose titration
- High (20–30% develop ≥3 mature follicles without careful monitoring)
- Subcutaneous injection, daily for 7–14 days
- Second-line for clomiphene/letrozole failure. Requires intensive ultrasound monitoring for OHSS prevention
- Kisspeptin 54 Protocol
- GnRH neuron stimulation. Restores physiological LH pulsatility and corrects hypothalamic pulse generator frequency
- 85–92% in clinical trials (clomiphene-resistant cohorts)
- Very low (single dominant follicle in 90% of responders)
- Intravenous or subcutaneous infusion, 8–12 hours
- Experimental. Most physiological mechanism but requires infusion access and precise dose timing